National Research Corporation Common Stock (Delaware) (NRC) fair value

ACCE thesis

National Research Corporation sells patient experience and healthcare performance surveys and analytics to hospitals and health systems, with its NRC Health platform and benchmarking databases forming the core of the business. Its moat rests on long-running benchmark datasets that hospitals use for regulatory-linked and reimbursement-linked quality reporting, which makes switching costs real and gives the franchise a recurring, sticky revenue base. Revenue growth of 4.0% is modest, and the trailing P/E of 84.0 reflects depressed or one-off earnings rather than a premium on the business, while the forward P/E of 17.2 implies the market expects earnings to normalise. Operating margin of -0.2% against a 61.7% gross margin says the spread between gross profit and overhead is the thing to examine, since small changes in cost discipline or sales efficiency would move profitability sharply. With a market capitalisation of roughly $446M, a 42.0% ROE and a score of 55/100, the name is small, unindexed and under-followed, which is precisely where a deeper look at the earnings bridge from trailing to forward is worth the time.